EOM Pharmaceuticals Holdings, Inc. (IMUC)
- Previous Close
0.1840 - Open
0.2100 - Bid --
- Ask --
- Day's Range
0.2100 - 0.2100 - 52 Week Range
0.1100 - 0.4000 - Volume
168 - Avg. Volume
3,200 - Market Cap (intraday)
23.787M - Beta (5Y Monthly) 1.19
- PE Ratio (TTM)
0.02 - EPS (TTM)
10.2200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.
www.eompharma.comRecent News: IMUC
Performance Overview: IMUC
Trailing total returns as of 5/8/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IMUC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IMUC
Valuation Measures
Market Cap
20.84M
Enterprise Value
20.84M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-3.69
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-440.45%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-5.13M
Diluted EPS (ttm)
10.2200
Balance Sheet and Cash Flow
Total Cash (mrq)
551.18k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.99M